Cargando…

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations

X-linked hypophosphataemia (XLH) is caused by a pathogenic variant in the PHEX gene, which leads to elevated circulating FGF23. High FGF23 causes hypophosphataemia, reduced active vitamin D concentration and clinically manifests as rickets in children and osteomalacia in children and adults. Convent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padidela, Raja, Cheung, Moira S, Saraff, Vrinda, Dharmaraj, Poonam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707830/ https://www.ncbi.nlm.nih.gov/pubmed/33112809 http://dx.doi.org/10.1530/EC-20-0291

Ejemplares similares

SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
por: Seefried, Lothar, et al.
Publicado: (2023)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations
por: Daniel, Anjali B., et al.
Publicado: (2018)

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy
por: Oldroyd, Alexander G S, et al.
Publicado: (2022)

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)
por: Glorieux, Francis H., et al.
Publicado: (2022)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

Metabolic bone disease of prematurity—National survey of current neonatal and paediatric endocrine approaches
por: Chinoy, Amish, et al.
Publicado: (2020)

Neonatal Bone Disorders
por: Saraff, Vrinda, et al.
Publicado: (2021)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

The ankle in XLH: Reduced motion, power and quality of life
por: Akta, Celine, et al.
Publicado: (2023)

Clinical Guidelines for Cystic Fibrosis Care: Summary of Guidelines Prepared by a Working Group of the Cystic Fibrosis Trust, the British Paediatric Association and the British Thoracic Society
por: Jackson, Anthony
Publicado: (1996)

Gynaecological infections in paediatric and adolescent gynaecology: a review of recommendations
por: Plagens-Rotman, Katarzyna, et al.
Publicado: (2021)

Phenotypes of a family with XLH with a novel PHEX mutation
por: Yamamoto, Akiko, et al.
Publicado: (2020)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Relationship between abdominal adiposity, cardiovascular fitness, and biomarkers of cardiovascular risk in British adolescents
por: Lewitt, Moira S., et al.
Publicado: (2020)

Adolescents With Eating Disorders in Pediatric Practice – The European Academy of Paediatrics Recommendations
por: Rynkiewicz, Agnieszka, et al.
Publicado: (2022)

Young XLH Patients-Reported Experience with a Supportive Care Program
por: Rothenbuhler, Anya, et al.
Publicado: (2023)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH)
por: Raimann, Adalbert, et al.
Publicado: (2020)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-Linked Hypophosphatemia (XLH)
por: Ross, Ryan, et al.
Publicado: (2023)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
por: Carpenter, Kelsey A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cdefi0fr4su7tiokr77ku4cfp4